Stifel Canada Weighs in on Cipher Pharmaceuticals Inc.'s Q3 2024 Earnings (TSE:CPH)

Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stifel Canada lifted their Q3 2024 earnings estimates for Cipher Pharmaceuticals in a report issued on Tuesday, September 24th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of $0.27 for the quarter, up from their prior forecast of $0.25. Stifel Canada currently has a "Strong-Buy" rating on the stock. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.42 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals' FY2024 earnings at $0.93 EPS.

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last posted its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$7.26 million during the quarter, compared to the consensus estimate of C$7.52 million.

A number of other analysts also recently issued reports on CPH. Stifel Nicolaus raised their price objective on shares of Cipher Pharmaceuticals from C$16.00 to C$17.00 and gave the stock a "buy" rating in a report on Wednesday. Leede Financial downgraded shares of Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

TSE CPH traded down C$0.97 during trading hours on Thursday, reaching C$13.28. 170,300 shares of the company were exchanged, compared to its average volume of 46,336. Cipher Pharmaceuticals has a 1 year low of C$4.10 and a 1 year high of C$19.69. The business's 50 day simple moving average is C$14.43 and its 200-day simple moving average is C$10.64. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of C$339.84 million, a P/E ratio of 10.80 and a beta of 1.25.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.